Rare lymphomas in routine practice-Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms.
Waldenström's macroglobulinaemia
disease management
lymphoma, B-cell
outpatients
prognosis
registries
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
25
11
2019
revised:
02
04
2020
accepted:
14
04
2020
pubmed:
10
5
2020
medline:
1
9
2020
entrez:
9
5
2020
Statut:
ppublish
Résumé
Waldenström's macroglobulinaemia (WM) is a rare indolent B-cell lymphoma for which only little prospective phase III evidence exists. Thus, real world data are important to provide insight into treatment and survival. We present here data on choice and outcome of systemic treatment of patients with WM treated in German routine practice. In total, 139 patients with WM who had been documented in the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms (NCT00889798) were included into this analysis. We analysed the most frequently used first-line and second-line treatments between 2009 and 2017 and examined best response, progression-free survival (PFS) and overall survival (OS). Bendamustine plus rituximab, with a median of six cycles, was by far the most frequently used first-line treatment (81%). Second-line treatment was more heterogenous and mainly based on bendamustine, cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP), fludarabine or ibrutinib, the latter approved in 2014. Three-year PFS from start of first-line treatment was 83% (95% confidence interval [CI] 74%-88%), 3-year OS was 87% (95% CI 80%-92%). These prospective data give valuable insights into the management and outcome of non-selected patients with WM treated in German routine practice. In the lack of prospective phase III clinical trials, real world data can help bridging the gap of evidence.
Identifiants
pubmed: 32383192
doi: 10.1002/hon.2740
pmc: PMC7497085
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
344-352Subventions
Organisme : Celgene GmbH
Organisme : Mundipharma GmbH
Organisme : Onkovis GmbH
Organisme : Roche Pharma AG
Informations de copyright
© 2020 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Blood. 2014 Mar 13;123(11):1637-46
pubmed: 24366360
Am J Hematol. 2011 Jun;86(6):479-83
pubmed: 21509798
Hematol Oncol Clin North Am. 2018 Oct;32(5):875-890
pubmed: 30190025
Blood. 2013 Nov 7;122(19):3276-82
pubmed: 24004667
Blood. 2014 Aug 28;124(9):1404-11
pubmed: 25027391
J Clin Oncol. 2007 Aug 1;25(22):3344-9
pubmed: 17577016
Eur J Haematol. 2019 Nov;103(5):460-471
pubmed: 31314918
Br J Haematol. 2018 Nov;183(4):564-577
pubmed: 30198549
Clin Genitourin Cancer. 2017 Apr;15(2):e209-e215
pubmed: 27720164
Hematol Oncol. 2015 Mar;33(1):15-22
pubmed: 24733536
Blood. 2009 Apr 30;113(18):4163-70
pubmed: 19196866
Oncologist. 2016 Nov;21(11):1377-1386
pubmed: 27473042
N Engl J Med. 2015 Apr 9;372(15):1430-40
pubmed: 25853747
Br J Haematol. 2000 Mar;108(4):737-42
pubmed: 10792277
Lancet Haematol. 2018 Jul;5(7):e275-e276
pubmed: 29958567
JAMA Oncol. 2017 Sep 1;3(9):1257-1265
pubmed: 28056114
Br J Haematol. 2015 Apr;169(1):81-9
pubmed: 25521528
Ann Hematol. 2018 Dec;97(12):2437-2445
pubmed: 30069704
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Am J Hematol. 2013 Jan;88(1):60-5
pubmed: 23165980
Lancet Haematol. 2018 Jul;5(7):e299-e309
pubmed: 29958569
Ann Hematol. 2018 Aug;97(8):1417-1425
pubmed: 29610969
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Hematol Oncol. 2020 Aug;38(3):344-352
pubmed: 32383192
Leukemia. 2009 Jan;23(1):153-61
pubmed: 18818699
Br J Haematol. 2018 Apr;181(1):77-85
pubmed: 29468652
J Clin Oncol. 2013 Jan 20;31(3):301-7
pubmed: 23233721
Br J Haematol. 2014 May;165(3):316-33
pubmed: 24528152
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Lancet. 2013 Apr 6;381(9873):1203-10
pubmed: 23433739
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv41-iv50
pubmed: 29982402
Br J Haematol. 2017 Oct;179(1):106-115
pubmed: 28677830
Haematologica. 2015 Nov;100(11):e446-9
pubmed: 26294729
Blood Rev. 2015 Sep;29(5):301-19
pubmed: 25882617
J Clin Oncol. 2018 Sep 20;36(27):2755-2761
pubmed: 30044692
Oncol Res Treat. 2014;37(11):635-6, 638-44
pubmed: 25486127
N Engl J Med. 2018 Jun 21;378(25):2399-2410
pubmed: 29856685
Leuk Res. 2008 Jan;32(1):55-9
pubmed: 17416416
Leukemia. 2019 Nov;33(11):2654-2661
pubmed: 31118465